Pulmonary fibrosis (PF) is a progressive interstitial lung disease (ILD) characterized by excessive fibrotic tissue ...

Environmental and Occupational Exposure: Chronic inhalation of inorganic and organic particulates, such as silica, asbestos, ...

Jakafi ® (ruxolitinib) net product revenues of $709 million in Q1'25 (+24% Y/Y); increasing full year 2025 Jakafi guidance to ...

Niktimvo is the first anti-CSF1R antibody approved to target the inflammation and fibrosis associated with chronic GVHD and we are already seeing the impact it is having for patients giving us ...

Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings. The new data from the 1,178-patient FIBRONEER-ILD study ...

Pak Navy Chief's Alarming Statement As Islamabad Fears Indian Naval Strike Amid soaring tensions with India, Pakistan appears to be trembling at the prospect of a massive naval strike. In a show ...

1 Non-GAAP cost of product revenues excludes the amortization of licensed intellectual property for Iclusig relating to the acquisition of the European business of ARIAD Pharmaceuticals, Inc. and ...